NASDAQ: FRNM · Industrial Applications and Services · 3 alerts · CIK 2017526
Share price
$10.09Close, Nov 16
Market cap
$1.13B
Shares outstanding
111.5MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Freenome, Inc. filings on SEC EDGAR ↗
Freenome, Inc. completed a business combination with Perceptive Capital Solutions Corp. on July 20, 2026, and is currently focused on developing blood-based screening tests like SimpleScreen CRC and SimpleScreen Lung. The company reports significant ongoing net losses and anticipates the need for additional capital to fund operations and commercialization efforts.
Freenome reported its first quarterly results as a public company, highlighted by $183.5 million in revenue following the FDA approval of its SimpleScreen CRC blood test. The company achieved GAAP net income of $60.1 million, a significant turnaround from a net loss in the prior year, and ended the quarter with $430 million in cash and marketable securities.
Term
Q3 2026
“Freenome made meaningful progress in its first quarter as a public company, executing on our strategic partnerships and strengthening our operating foundation.”
Freenome launched its SimpleScreen Lung test, a blood-based screening tool for adults aged 50-80 with a significant smoking history. The company also introduced a first-of-its-kind offering that allows eligible patients to be screened for both lung and colorectal cancer (CRC) through a single blood draw using two independently validated tests.